Precision Medicine and Precision Diagnostics

All healthcare starts with diagnosis. Diagnostics for precision medicine must:

  • Provide specific characterization of an individual patient’s unique disease and biology.
  • Accurately identify individual patients who will and who will not respond to therapies that are increasingly targeted and increasingly expensive.
  • Create an environment for an efficient healthcare system.

GreyBird has the goal to invest in companies that can help to eliminate “trial and error” medicine with high-specificity diagnostics and generate value for patients, providers, developers of therapies, and those who pay for healthcare.


For every patient that they help, the ten highest grossing drugs in the United States fail to help up to 24 people.

Why Invest in Precision Diagnostics

GreyBird Investment Opportunities

In spite of growing R&D expenditures, truly new technologies are not coming from the largest multi-national diagnostic technology companies. They are coming from entrepreneurs, who are creating an appetite for M&A. The demand for our portfolio is already here.


Industry Dynamics
  • Poor development productivity
  • Lack of organic growth
  • Risk reduction
  • M&A initiatives
Scientific Discovery
  • ‘Omics revolution
  • New detection technologies
  • Targeted therapies
  • Personal monitoring devices
  • Advanced analytics
Healthcare Economics
  • Access vs. cost control
  • Global structural growth
  • Global clinical trials
  • Unnecessary, ineffective, and inefficient care avoidance


We will improve health and create wealth, by investing in technologies to change healthcare from probabilistic and population-based, to precise, predictive and personal.

Our Approach and Why it Matters

1. Dedicated Focus

Next generation Precision Diagnostics, where we have deep domain competence and market tailwinds

2. Investor Friendly

We openly share investment analyses and preserve an opt-out option for our investors

3. Global Influence

We have proprietary connections to global companies, markets, and trend-setting projects

4. Engaged Diligence

We are not passive investors, starting with an operational engagement even before we invest

5. Transformational Companies

We can afford to be patient and will invest only in companies we believe can have a disruptive impact and the potential for large exit multiples

Our unique “Engaged Diligence” process dramatically increases transparency

We skip the typical due-diligence show and instead, during our months-long Engaged Diligence we learn about the company and its people, products, and processes:

  • Join boards
  • Craft clinical trials
  • Solve technical problems
  • Draft strategy plans
  • Identify operational issues
  • Find strategic partners


“GreyBird was extremely helpful to us well prior to their investment. They helped shape our strategy, opined on marketing documents, helped shape our presentations, and even contributed family members as beta testers. They remain deeply involved and committed to our success.”

Zeb Kimmel, CEO, Atlas5D

“GreyBird helped us see the necessity of narrowing the scope of our product investments to a solution that accelerated our initial market penetration. They also provided much-needed introductions to strategic partners. While we cannot (yet) count ourselves among their portfolio companies, we have greatly benefitted from their ‘engaged diligence’ process.”

Nick Berens, CEO, TransMed

“Prior to investing, GreyBird helped us to craft our business plan and focus on the commercialization of the Lyme test as our first product. They have introduced us at very high levels to potential strategic partners and never fail to give us some free advertising whenever possible.”

Ross Dunlap, CEO, Ceres Nanosciences

“GreyBird claims that they are not passive investors – and they are not. They encourage, demand and help us improve as individuals and as a company. As Board Members, they provide guidance and exert control as appropriate, but always leave enough room for the CEO to lead and continue to develop. We feel fortunate that they chose to invest in our company.”

Jochen Kohlhaas, CEO, Hummingbird Diagnostics

Our “Ethical Filter” is both a moral and a financial asset
  • Solves a serious or unsolved problem?
  • Cost-effective?
  • Possible new Standard of Care?
  • Potential for inappropriate use?
  • Potential negative consequences?
  • Potential for harm?
  • Would I recommend it for my family?
  • Would I pay for it myself?

Regulatory approval proves medical benefit? We disagree. Reimbursed technologies that have been exploited or result in unnecessary care are too numerous to list. We take this one step further and analyze eight questions to help determine medical appropriateness and long-term clinical consequences. The advantage is not only humanitarian. It reduces risk of poor global acceptance or a future disruptive reimbursement decrease. 
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.


For additional information, please contact: